In this era of tumor genomics, proteomics, and metabolomics, the idea that fundamental insights about cancer could emerge from observations of the gross characteristics of individual persons (i.e., from classical epidemiology) seems almost anachronistic. Surely the era of discovery of common exposures with broad effects on cancer is over. Or is it?
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In this issue of the Journal, Giovannucci et al. ( 1 ) report that estimates of vitamin D status derived from the Health Professionals Follow-up Study were associated with statistically signifi cant reductions in total cancer incidence and mortality. Most of the protective effect for vitamin D status comes from an exposure that is common indeed -sunlight. Because many persons think of sunlight only as a cause of cancer (especially melanoma), some perspective may be helpful.
In 1941, Frank Apperly ( 2 ) , a pathologist, demonstrated an inverse correlation between levels of ultraviolet radiation in North America and mortality rates from cancers in nonskin sites and proposed that sunlight somehow conferred " a relative cancer immunity " to nonskin cancers. Although Apperly's paper attracted little attention in its day, epidemiologists rediscovered his fundamental insight half a century later. Many common cancers, such as cancers of the colon and prostate, display fascinating north -south gradients, with rates that increase systematically with increasing geographic latitude, and show an increased risk among African Americans ( 3 ) . The increased risk with residence at northern latitudes and greater incidence and mortality in persons with dark pigmentation recall the descriptive epidemiology of rickets, the classic disease of vitamin D defi ciency. These considerations led several epidemiologists, including Garland and Garland ( 4 ) for the colon in 1980, and Schwartz and Hulka ( 5 ) for the prostate in 1990, to propose that vitamin D defi ciency increased the risk for these cancers. Similar claims later were made for cancers at other sites, e.g., breast, ovary, and pancreas, so that vitamin D has become a prime candidate for cancer prevention ( 6 , 7 ) .
Understanding how vitamin D could infl uence cancer risk requires an understanding of vitamin D synthesis. The synthesis of vitamin D begins with the production of vitamin D 3 (cholecalciferol) after 7-dehydrocholesterol in the skin is exposed to ultraviolet B radiation (wavelength = 290 -315 nm). Because melanin is an effective sunscreen, given the same ultraviolet exposure, blacks synthesize less vitamin D than whites, accounting for the far higher prevalence of vitamin D defi ciency among blacks ( 8 ) . ( 7 , 17 , 18 ) linking vitamin D status with reduced cancer risk and are some of the most compelling yet. The results, with lower risks of most (but not all) forms of cancer, are also some of the most broad based, and they indicate that vitamin D may have a role in most human tumors.
Although the cohort fi ndings are likely to increase enthusiasm for the cancer prevention potential of vitamin D, inherent limitations of observational epidemiologic studies combined with a history of prior disappointments with other potential chemopreventive agents suggest caution in their interpretation. Two decades ago there was intense interest and hope that supplementation with β -carotene might reduce the risk of several cancers. Epidemiologic studies have consistently reported that men and women with the highest dietary intakes of β -carotene as well as with elevated blood levels experienced lower risks of respiratory, gastrointestinal, and other cancers. The zeal was crushed, however, when randomized trials in the United States and Finland showed increased rather than decreased risks of lung cancer among adults receiving β -carotene supplements ( 19 , 20 ) . Vitamin E was similarly touted as an inhibitor of cancer, as well as of cardiovascular disease, but again the " gold standard " of randomized trials failed to confi rm the preventive correlations noted in cohort and casecontrol studies ( 21 ) . Epidemiologic studies also strongly indicated that hormone replacement therapy might not only relieve menopausal symptoms but also lower the risk of heart disease and breast and other cancers, but again, when clinical trials were conducted, no benefi t with respect to these conditions accrued to women administered the therapy ( 22 ) . In each of these examples, the agents may have demonstrated benefi t with modifi cation of the dose, formulation, or timing of the intervention or with longer follow-up, but the sobering lesson is that trends observed in nonexperimental settings, including cohort studies, are not always confi rmed experimentally when tested in randomized clinical trials. Science, after all, is a continual process of hypothesis formulation, testing, and refi nement; ecologic (e.g., geographic correlations) and analytic (e.g., cohort and case -control) studies provide the evidence-based clues to cancer etiology, but randomized trials are generally needed to confi rm these leads and develop effective disease prevention strategies.
Will a similar unrealized promise eventually befall vitamin D? We hope not. Although ex post facto mechanistic explanations can often be postulated to explain epidemiologic observations, for vitamin D the biologic evidence for inhibition of carcinogenesis is strong and, often, was predicted by the prior epidemiologic fi ndings on sunlight exposure. Laboratory and observational epidemiologic research will continue to further elucidate and refi ne hypotheses on vitamin D's role, but the potential for cancer prevention by vitamin D (in pill form) must now proceed to the clinical trial testing arena. Several randomized trials have assessed the effects of vitamin D supplementation on bone fracture ( 23 ) , but few have assessed its preventive effect on the risk of cancer or precancerous lesions [although small trials are evaluating 1,25(OH) 2 D or it is analogs on the treatment of prostate and other cancers].
We close with the recognition that heavy sun exposure can cause harm. Because the ultraviolet radiation action spectra required for vitamin D synthesis and the spectra that induce DNA damage are essentially the same, there is an apparent confl ict between the advantages of sunlight exposure for vitamin D synthesis and its deleterious effects, the most serious being malignant melanoma. Although much has been made of it in the lay press, and by some in the dermatology community, the confl ict may be more apparent than real ( 24 ) . The amount of sun needed to produce adequate levels of vitamin D, at least for bone health, is modest and can be obtained in a light-skinned person by a brief afternoon summertime stroll. Although the dose -response relation between ultraviolet exposure and the development of melanoma is not well quantifi ed, the limited exposure required for vitamin D synthesis is likely at the very low end of the curve.
Sunlight generally is an effective means of generating large amounts of vitamin D, but it may not be safe for all persons. For many individuals, including those who are darkly pigmented or who live at northern latitudes, sunlight exposure may also be insuffi cient to generate adequate vitamin D. Conversely, vitamin D supplements are widely available, inexpensive, and believed to be safe over a large dosing range. As is often pointed out, the present recommended allowance for vitamin D -400 IU -for individuals aged 50 -70 years is inadequate even to maintain skeletal health and is probably too low for meaningful anticancer effects ( 25 ) . A dose of 400 IU of vitamin D 3 will raise serum levels of 25(OH)D 3 only modestly, by about 7 nmol/L or less than 3 ng/mL. The use of this low dose, in conjunction with the relatively short duration of the trial, may explain the recent failure of vitamin D to reduce the incidence of colorectal cancer in the Women's Health Initiative ( 26 ) .
In summary, a role for sunlight and vitamin D in cancer prevention is strongly suggested by epidemiologic observations, including the fi ndings of Giovannucci et al. ( 1 ) , and potential mechanisms have been identifi ed by experimental studies. The promising results from both observational and laboratory studies should usher in a new era of intervention studies of vitamin D and cancer risk. Because many public health scientists are already clamoring for higher levels of vitamin D supplementation for bone and other health, randomized trials of vitamin D and cancer risk should be undertaken speedily ( 27 ) . If the promise of vitamin D holds, a brief walk in the sun may turn out to be a step toward cancer prevention.
